Estimating AIDS-Free Survival in a Severely Immunosuppressed Asymptomatic HIV-Infected Population in the Era of Antiretroviral Triple Combination Therapy
- 1 April 1999
- journal article
- clinical trial
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 20 (4), 376-381
- https://doi.org/10.1097/00042560-199904010-00008
Abstract
Antiretroviral triple combination therapies have been evaluated in randomized controlled trials and cohort studies. Little is known about their impact on asymptomatic, severely immunosuppressed, HIV-infected individuals in a real world population. To describe disease progression in a broad asymptomatic population of HIV-infected individuals with a CD4 count or =100 cells/mm3, (2) CD4 count 75 to 99 cells/mm3, (3) CD4 count 50 to 74 cells/mm3, (4) CD4 count 0 to 49 cells/mm3, and AIDS. Swiss HIV Cohort Study database. A total of 1027 patients contributed to 2634 pairs of 6-month observations from 1993 to 1995, and 681 patients contributed to 2077 pairs of 6-month observations from 1996 to 1997. AIDS-free survival probabilities and the expected AIDS-free survival time. The expected number of AIDS-free months in a 3-year period was 17 (95% confidence interval [CI], 16-19) for patients starting in state 4 prior to 1996 versus 26 months (95% CI, 24-28) for patients starting in state 4 after 1996. For these two time periods, the corresponding expected numbers of AIDS-free months were 21 (95% CI, 20-22) versus 30 (95% CI, 28-32) for state 3 and 23 (95% CI, 21-24) versus 33 (95% CI, 32-34) for state 2. Expected 3-year AIDS-free survival in severely immunosuppressed individuals with CD4 counts <100 cells/mm3 improved significantly between 1993 to 1995 and 1996 to 1997.Keywords
This publication has 10 references indexed in Scilit:
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral TherapyJAMA, 1998
- A Critical Assessment of the Prognostic Value of HIV-1 RNA Levels and CD4+ Cell Counts in HIV-Infected PatientsArchives of Internal Medicine, 1998
- Randomised placebo-controlled trial of ritonavir in advanced HIV-1 diseaseThe Lancet, 1998
- Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre studyBMJ, 1997
- A Markov model for HIV disease progression including the effect of HIV diagnosis and treatment: Application to AIDS prediction in England and WalesStatistics in Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristicsInternational Journal of Public Health, 1994
- Markov Models in Medical Decision MakingMedical Decision Making, 1993
- The Markov Process in Medical PrognosisMedical Decision Making, 1983